Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab

Affiliations

• ¹ Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan. [email protected].
• ² Cancer Treatment Center, Kansai Medical University, 2‑3‑1, Hirakatashinmachi, Hirakata, Osaka, 573‑1191, Japan. [email protected].
• ³ Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2‑1‑1, Minatojima Minamimachi, Chuo‑Ku, Kobe, Hyogo, 6500047, Japan.
• ⁴ Department of Internal Medicine, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan.
• ⁵ Department of Surgery, Himeji Red Cross Hospital, 1‑12‑1, Shimoteno, Himeji, Hyogo, 6708540, Japan.